Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing hydroxycarbamide (hydroxycarbamide)

08.09.2021 1220 views

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of the Periodic Safety Update Reports (PSURs) for medicinal products containing hydroxycarbamide (hydroxycarbamide), drew the following conclusions:

In view of the available data on hemolytic anemia from the literature and spontaneous reports, and in view of the plausible mechanism of action, the PRAC established a causal relationship between hydroxycarbamide and hemolytic anemia. The PRAC concluded that registration certificate holders of medicinal products containing hydroxycarbamide should make appropriate changes to the instructions for medical use.

Update of the sections “Special warnings and precautions for use” and “Adverse reactions” of the instructions for medical use, adding a warning about the occurrence of hemolytic anemia and the adverse reaction hemolytic anemia with the frequency “Not known”.

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the scientific conclusions drawn by PRAC.

Based on the scientific conclusions regarding hydroxycarbamide, the CMDh is of the opinion that the benefit-risk balance of medicinal products containing hydroxycarbamide remains unchanged, taking into account the proposed changes to the instructions for medical use.

Amendments to be included in the relevant sections of the instructions for medical use (new text underlined in bold, deleted text struck through).

“Special precautions for use” section

The following changes should be made to the warnings:

Cases of hemolytic anemia have been reported in patients receiving hydroxycarbamide for the treatment of myeloproliferative diseases. Patients who develop severe anemia should undergo laboratory tests to determine hemolysis. If hemolytic anemia is diagnosed, the use of hydroxycarbamide should be discontinued.

“Adverse reactions” section

The following adverse reaction should be added to blood and lymphatic system disorders with the frequency “Not known”:

  • Hemolytic anemia
Перелік лікарських засобів, що містять гідроксикарбаміду (hydroxycarbamide) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 01.09.2021)

Linkhttps://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-scientific-conclusions-grounds-variation-terms-marketing-authorisation-amendments/00009182/202012_en.pdf